Michael Devereaux
Neurology · Cleveland, OHNPI 1962420430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $795 and has fallen 89.7% since, to $82 in 2024.
Across 86 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$348
- UCB, Inc.$247
- Novartis$154
- Amgen$138
- Greenwich Biosciences, Inc.$137
- Eisai Inc.$131
- plus $584 from 16 others
What the payments were for
- Food & beverage$1,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $348 |
| UCB, Inc. | 11 | $247 |
| Novartis | 10 | $154 |
| Amgen(2 entities) | 6 | $138 |
| Greenwich Biosciences, Inc. | 6 | $137 |
| Eisai Inc. | 7 | $131 |
| SK Life Science, Inc. | 4 | $85 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Sunovion Pharmaceuticals Inc. | 6 | $74 |
| EMD Serono, Inc. | 5 | $70 |
| Argenx US, Inc. | 3 | $62 |
| Sanofi | 3 | $52 |
| Merz North America, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$125
How this compares
$1,739 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.